Aviral Vatsa
A
thread 1/4
🧠 Exciting news from a recent NCI-funded clinical trial on craniopharyngioma, a rare brain tumor. Traditional treatments often required surgery or radiation, but new targeted therapies might change that. #BrainTumorResearch
02:27 AM - Aug 13, 2023
Avatar
0
3
1
Aviral Vatsa
A
thread 2/4
📊 The trial tested a combination of vemurafenib (Zelboraf) & cobimetinib (Cotellic). Results? Tumors shrank substantially in 15 out of 16 participants. Many saw positive responses for an average of 22 months without additional treatments. #CancerBreakthrough
02:27 AM - Aug 13, 2023
1
0
Aviral Vatsa
A
thread 3/4
🔬 The key? These tumors have a BRAF V600E mutation. The drugs specifically target this mutation, offering a more tailored treatment approach. While not yet FDA-approved for this use, it's already making its way into patient care. #TargetedTherapy
02:28 AM - Aug 13, 2023
1
0
Aviral Vatsa
A
thread 4/4
🤔 This study opens doors for more personalized treatments in rare cancers. With fewer side effects and targeted action, the future looks promising for patients with craniopharyngioma and potentially other rare tumors. #HopeForTheFuture
02:28 AM - Aug 13, 2023
0
0

 

{{ notificationModalContent }} {{ promptModalMessage }}